Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cyclenium Pharma and Fundación Fundación Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía (MEDINA) have reached a drug discovery and collaboration agreement to develop new anti-infective drug candidates.
Subscribe to our email newsletter
Fundación MEDINA is a non-profit research organization formed through a private-public partnership between the Government of Andalucía (Spain), the University of Granada and Merck Sharp and Dohme de España.
As part of the partnership, Cyclenium’s proprietary QUEST Library of next generation macrocyclic molecules and associated hit-to-clinical candidate optimization capabilities will be used in along with the extensive expertise and experience of Fundación MEDINA in infective disease research.
The new anti-infective drug candidates that will be discovered are expected to prove effective against a number of clinically significant bacterial and fungal pathogens.
Fundación MEDINA scientific director Dr Olga Genilloud said: "This relationship represents a strategic collaboration to identify novel drugs in the area of infectious diseases from the exploitation of Cyclenium’s unique library complementing the chemical diversity of our natural product libraries.
"MEDINA provides the expertise and tools to maximize the probability of success in the collaboration with Cyclenium and the discovery of promising compounds for the treatment of serious multidrug resistant infections."
The collaboration is the fourth such agreement reached by Cyclenium with other firms in the last one year.